As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the ...

Roche has secured approval from the US Food and Drug Administration for Ocrevus Zunovo with Halozyme's Enhanze drug delivery ...

China’s NMPA granted BTD for Blenrep (belantamab mafodotin) combined with BorDex for the treatment of multiple myeloma.

Having a specialty logistics partner that can act as lookout for pharmaceutical manufacturers is critical amid supply chain ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

As Ipsen pivots away from Cabometyx in mCRPC, US rights holder Exelixis will press ahead with a submission to the FDA.

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape. The most common ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to Neuraptive Therapeutics’ ...